Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure

Journal of Clinical Pharmacology

Volumn 55, Issue 11, 2015, Pages 1236-1247

  Vu, Thuy ^a   Ma, Peiming ^a,b   Xiao, Jim J ^a,c   Wang, Yow Ming C ^a,d   Malik, Fady I ^e   Chow, Andrew T ^a  

^a AMGEN INC   (United States)

^b GLAXOSMITHKLINE   (China)

^c Clovis Oncology Inc   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e Cytokinetics Inc   (United States)

Author keywords

cardiac myosin activator; CK 1827452; inotrope; NONMEM; omecamtiv mecarbil; population PK PD; stable heart failure; systolic ejection time

Indexed keywords

OMECAMTIV MECARBIL; CARDIAC MYOSIN; UREA;

ARTICLE; CARDIAC PATIENT; CENTRAL VOLUME OF DISTRIBUTION; CLINICAL TRIAL (TOPIC); COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ELIMINATION HALF-LIFE; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; SYSTOLE; ADULT; AGED; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; AGED; CARDIAC MYOSINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; STROKE VOLUME; SYSTOLE; UREA; YOUNG ADULT;

EID: 84942843708     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.538     Document Type: Article

References (26)

1. Adams KF Jr, Fonarow GC, Emerman CL, et al., Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149 (2): 209-216.
2. Yancy CW, Jessup M, Bozkurt B, et al., 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128 (16): 1810-1852.
3. Teerlink JR, Metra M, Zaca V, et al., Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009; 14 (4): 243-253.
4. Hasenfuss G, Teerlink JR., Cardiac inotropes: current agents and future directions. Eur Heart J 2011; 32 (15): 1838-1845.
5. Cuffe MS, Califf RM, Adams KF Jr., et al., Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287 (12): 1541-1547.
6. Felker GM, Benza RL, Chandler AB, et al., Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41 (6): 997-1003.
7. Cohn JN, Goldstein SO, Greenberg BH, et al., A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998; 339 (25): 1810-1816.
8. Teerlink JR., A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009; 14 (4): 289-298.
9. Malik FI, Hartman JJ, Elias KA, et al., Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331 (6023): 1439-1443.
10. Teerlink JR, Clarke CP, Saikali KG, et al., Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011; 378 (9792): 667-675.
11. Shen YT, Malik FI, Zhao X, et al., Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010; 3 (4): 522-527.
12. Barrett KE, Boitano S, Barman SM, Brooks HL., The heart as a pump. In: Ganong's Review of Medical Physiology, 24th ed. New York, NY: McGraw-Hill Companies; 2012.
13. Weissler AM, Peeler RG, Roehll WH Jr., Relationships between left ventricular ejection time, stroke volume, and heart rate in normal individuals and patients with cardiovascular disease. Am Heart J 1961; 62: 367-378.
14. Cleland JG, Teerlink JR, Senior R, et al., The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378 (9792): 676-683.
15. Oh JK, Seward JB, Tajik AJ., The Echo Manual. 3rd ed. New York: Lippincott Williams & Wilkins; 2006.
16. R:A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2013.
17. Zhang L, Beal SL, Sheiner LB., Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 2003; 30 (6): 387-404.
18. Karlsson MO, Savic RM., Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82 (1): 17-20.
19. Akaike H., A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19 (6): 716-723.
20. Efron B, Tibshirani RJ., An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
21. Karlsson MO, Holford N., A tutorial on visual predictive checks. Annual Meeting of the Population Approach Group in Europe 2008: 17.
22. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13 (2): 143-151.
23. Xu XS, Dunne A, Kimko H, Nandy P, Vermeulen A., Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. J Pharmacokinet Pharmacodyn 2011; 38 (4): 423-432.
24. Karlsson MO, Sheiner LB., The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21 (6): 735-750.
25. Wallace GC, Ramsden DB, Grant MH, Lyubimov AV., General principles of drug distribution. In: Encyclopedia of Drug Metabolism and Interactions. John Wiley & Sons, Inc.; 2011.
26. Morgan BP, Muci A, Lu PP, et al., Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Vhem Lett 2010; 1 (9): 472-477.